Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: an integrated analysis of two pivotal trials

J Sex Med. 2011 Jan;8(1):261-71. doi: 10.1111/j.1743-6109.2010.02005.x. Epub 2010 Aug 30.


Introduction: Men with erectile dysfunction (ED) are typically older and have one or more underlying cardiovascular conditions.

Aim: To determine the efficacy and safety of a new orodispersible tablet (ODT) formulation of vardenafil for the treatment of ED, and whether age, or the presence of underlying conditions affects treatment outcomes.

Methods: This is an integrated analysis of data from two phase III, double-blind, multicenter, randomized, parallel-group, placebo-controlled studies that compared 10 mg on-demand vardenafil ODT with placebo in a general population of men with ED, stratified so that approximately 50% of patients were aged ≥ 65 years. Results were reported by age (<6 5 vs. ≥ 65 years) and presence/absence of diabetes, dyslipidemia, or hypertension.

Main outcome measures: Primary measures were the erectile function domain of the International Index of Erectile Function (IIEF-EF) and Sexual Encounter Profile questions 2 (SEP2) and 3 (SEP3).

Results: Of the 701 men randomized (51% aged ≥ 65 years), 686 were included in the intent-to-treat population (placebo, n = 334; vardenafil ODT, n = 352). Vardenafil ODT was significantly superior to placebo for all primary efficacy measures, regardless of age, baseline ED severity, or underlying condition (P < 0.0001 for vardenafil vs. placebo for each endpoint). IIEF-EF scores and SEP2/3 success rates in older patients and men with underlying conditions were not significantly different to those of younger patients or men without underlying conditions. Adverse events (AEs) were mostly mild to moderate in severity, occurring with higher incidence in the vardenafil vs. placebo group. The most frequently reported drug-related AEs in the vardenafil group were headache, flushing, nasal congestion, dizziness, and dyspepsia, consistent with the known safety profile of phosphodiesterase type 5 inhibitors.

Conclusions: Vardenafil ODT significantly improves erectile function in men with ED regardless of age, baseline ED severity, or underlying condition.

Publication types

  • Meta-Analysis

MeSH terms

  • Age Factors
  • Aged
  • Biological Availability
  • Comorbidity
  • Diabetes Mellitus / epidemiology
  • Dosage Forms
  • Double-Blind Method
  • Dyslipidemias / epidemiology
  • Erectile Dysfunction / drug therapy*
  • Erectile Dysfunction / epidemiology
  • Humans
  • Hypertension / epidemiology
  • Imidazoles / administration & dosage*
  • Imidazoles / adverse effects
  • Imidazoles / pharmacokinetics
  • Male
  • Phosphodiesterase 5 Inhibitors / administration & dosage*
  • Phosphodiesterase 5 Inhibitors / adverse effects
  • Phosphodiesterase 5 Inhibitors / pharmacokinetics
  • Piperazines / administration & dosage*
  • Piperazines / adverse effects
  • Piperazines / pharmacokinetics
  • Randomized Controlled Trials as Topic
  • Sulfones / administration & dosage
  • Sulfones / adverse effects
  • Sulfones / pharmacokinetics
  • Triazines / administration & dosage
  • Triazines / adverse effects
  • Triazines / pharmacokinetics
  • Vardenafil Dihydrochloride


  • Dosage Forms
  • Imidazoles
  • Phosphodiesterase 5 Inhibitors
  • Piperazines
  • Sulfones
  • Triazines
  • Vardenafil Dihydrochloride